[2] Nutritional Concerns While Taking GLP-1 Medications Individuals taking GLP-1s may experience a significant appetite reduction, which can correspond to a caloric reduction of 16% to 39%
Ongoing cardiovascular outcomes trials (SYNCHRONIZE-CVOT for Survodutide) will provide definitive data on whether these metabolic improvements prevent heart attacks, strokes, and cardiovascular death
Future research: TRIUMPH phase 3 program Following the positive results from the NCT 04881760 study, Lilly is planning the TRIUMPH Phase 3 program, which will further test retatrutides impact on chronic weight management, obstructive sleep apnea, and knee osteoarthritis in people with obesity and overweight
Avoid excess sugar and processed foods (which have excess sugar)
Carcinoma medular de tiroides (MTC): Existe una advertencia en recuadro sobre el riesgo de MTC basada en estudios en animales
Caplan took the time to listen to me and after meeting with her I am feeling more hopeful